Anderson Elizabeth M's Form 4 filing
Revolution Medicines, Inc. (RVMD) · filed Sep 24, 2026
- Accession no.
- 0001758247-26-000004
- Filed
- Sep 24, 2026, 6:00 PM ET
- Trade date
- Sep 22, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.96M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Anderson Elizabeth MCIK 0001758247 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Common Stock | MOption exerciseAcquired | +5,070 | $1.12 | +$5,678.4 | 14,476 | Direct | |
| Sep 22, 2026 | Common Stock | SSaleDisposed | −910 | $191.85F2 | −$174,585.41 | 13,566 | Direct | |
| Sep 22, 2026 | Common Stock | SSaleDisposed | −4,985 | $192.54F3 | −$959,805.42 | 8,581 | Direct | |
| Sep 22, 2026 | Common Stock | SSaleDisposed | −2,648 | $193.44F4 | −$512,227 | 5,933 | Direct | |
| Sep 22, 2026 | Common Stock | SSaleDisposed | −1,500 | $194.59F5 | −$291,883.05 | 4,433 | Direct | |
| Sep 22, 2026 | Common Stock | SSaleDisposed | −100 | $195.15 | −$19,515 | 4,333 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Common Stock | MOption exerciseDisposed | −6,165 | $0.00 | $0 | 1,095 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The transaction was executed in multiple trades at prices ranging from $191.65 to $191.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The transaction was executed in multiple trades at prices ranging from $192.01 to $192.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The transaction was executed in multiple trades at prices ranging from $193.00 to $193.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The transaction was executed in multiple trades at prices ranging from $194.04 to $194.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.